ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway
Molecular Carcinogenesis · 2024-07 · 63 (7) · 1221-1234
DOI: 10.1002/mc.23719 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 22.03.2024. Verfasst von Hongqin Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Gemcitabine, Pancreatic Neoplasms, Deoxycytidine, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: This project was supported by The Affiliated Hospital of Xuzhou Medical University.
Abstract (Originalsprache)
Pancreatic cancer (PC), a leading cause of cancer‐related deaths, has a 5‐year survival rate of approximately 10%. α‐Enolase (ENO1) is a junction channel protein involved in tumor cell apoptosis and chemoresistance. However, the role of ENO1 in PC remains unclear. The expression and prognosis of ENO1 levels were determined in PC using public databases based on The Cancer Genome Atlas (TCGA) data sets. Cell viability, half maximal inhibitory concentration (IC50), autophagy, apoptosis, and autophagy markers were examined using cell counting kit‐8 (CCK‐8), transmission electron microscope, flow cytometry assays, and immunoblot, respectively. Using the Gene Expression Omnibus (GEO) and TCGA data sets, we found that ENO1 was significantly enriched in PC tumor tissues, and high expression levels of ENO1 were associated with an unfavorable prognosis. Whereas ENO1 silencing suppressed proliferation, autophagy, and induced cell apoptosis in PC cells, and inhibited tumor growth in vivo. Mechanistically, knockdown of ENO1 enhanced cellular cytotoxicity of gemcitabine (GEM), as well as reducing the expression of yes‐associated protein 1 (YAP1), a major downstream effector of the Hippo pathway in vitro. YAP1 promoted autophagy and protected PC cells from GEM‐induced apoptotic cell death. Furthermore, YAP1 overexpression attenuated the inhibition effects of ENO1 silencing. Our results suggest that ENO1 overexpression promotes cell growth and tumor progression by increasing the expression of YAP1 in PC. Further studies are required to understand the detailed mechanisms between ENO1 and YAP1 in PC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of Endocrinology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
- Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Förderung
- This project was supported by The Affiliated Hospital of Xuzhou Medical University
Zitieren
APA
Ma, H., Kong, L., Liu, L., Du, Y., Zhu, X., Wang, J., & Zhao, W. (2024). ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Molecular Carcinogenesis, 63(7), 1221-1234. https://doi.org/10.1002/mc.23719
Vancouver
Ma H, Kong L, Liu L, Du Y, Zhu X, Wang J, et al. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway. Molecular Carcinogenesis. 2024;63(7):1221-1234. doi:10.1002/mc.23719
BibTeX
@article{Ma2024,
author = {Ma, Hongqin and Kong, Lulu and Liu, Li and Du, Yusheng and Zhu, Xinguo and Wang, Ji and Zhao, Wenxing},
title = {ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway},
journal = {Molecular Carcinogenesis},
year = {2024},
volume = {63},
number = {7},
pages = {1221--1234},
doi = {10.1002/mc.23719}
}
EUVIMED